Primary-paper analysis for antibody engineering, VHH design, ADC development, protein modeling, and biologics AI—organized into core findings, novelty, limitations, and field context.
Latest issueIssue #8
In Vivo Antibody Click, Masked Cytokines, and Antibody Developability at Scale
Seven papers on in vivo ADC click chemistry, FN-EDB-gated IL-12, a 19,265-structure antibody glycosylation survey, bispecifics, QSP, and VHH imaging.
This week's thesis: Conditional and combinatorial targeting dominates this week: drugs assembled or unmasked only where two signals coincide, and large-scale structural data correcting the design rules underneath all of it.
Sequentially dosed antibody-TCO and ADC-tetrazine conjugates ligate inside the tumor via click chemistry, lifting trastuzumab uptake in HER2-ultralow tumors 3.2-fold and driving complete remissions in models that resist conventional ADCs.
A dual-specificity switch arm keeps IL-12 masked in circulation and unveils it only where the tumor matrix antigen FN-EDB competes it off, a trans-activation logic gate tuned with a QSP model and validated in cell assays.
Across 19,265 antibody structures, variable-domain N-glycosylation shows up at only 7.82%, about half the rate from prior enriched datasets; glutamine at the sequon X-position is not a suppressor after all, and N-X-T sequons are 3.84-fold more likely to be glycosylated than N-X-S.
One antibody against the GI-cancer antigen CDH17 is deployed two ways, as an MMAE/MMAF ADC and as a bispecific engaging a rare pan-Vδ1/Vδ2 gamma-delta T-cell agonist nanobody, exploiting the abundance of gamma-delta T cells in gut epithelium.
A monovalent PD-1/CTLA-4 bispecific engineered to steer CTLA-4 blockade onto PD-1-positive T cells reported first-in-human data in 86 patients: 19.8% objective response, 17.5-month median duration, and T-cell activation beyond approved combination regimens.
A mechanistic model jointly tracks AAV vector, expressed antibody, target antigen, and antibody-target complex across brain subregions, predicting that intra-cisterna magna or intrastriatal delivery beats high-dose IV for CNS target engagement.
One anti-FAP nanobody engineered into three formats maps how valency and molecular weight trade off in PET imaging: the monomer clears fast, the low-MW bivalent dimer maximizes tumor-to-blood ratio, and the Fc-fusion gives the highest, most durable uptake.
A phase 1 trial of DYP688, an ADC that delivers a Gq/11 signaling inhibitor otherwise too toxic to dose systemically, showed 19.7% objective response and 82% disease control in GNAQ/GNA11-mutant melanomas.
Researchers built a PROTAC that recruits a degradation enzyme to a disordered region of estrogen receptor alpha by routing through its structured partner protein 14-3-3, revealing an entirely new protein interface by cryo-EM.
A phase 1b trial tested an anti-PD-L1 antibody deliberately engineered for a short, roughly four-day half-life, dosed intermittently in early Alzheimer's patients, and found it safe with early signs of a neuroprotective biomarker effect.
A spatial computational model of liver cancer, calibrated directly against real tumor imaging data, shows that fibroblasts physically wall off tumors from immune cells and predicts which patients will respond to combination immunotherapy.
A synthetic antibody library engineered specifically for machine learning readout recovered antibodies against targets that a standard screen missed entirely.
A systematic study of 160 bispecific antibodies shows that some developability properties inherit predictably from the parent antibodies, while others only emerge once the two arms are combined.
A newly characterized molecular glue degrades a cancer-linked protein by having cereblon grip a surface tyrosine rather than the degron motif every prior cereblon-based glue has relied on.
A low-cost, high-throughput plate assay for antibody self-association turns out to predict in vivo clearance about as well as the field's leading specialized assays, and can now be predicted directly from sequence.
A proteome-wide screen of 174 approved and clinical-stage antibodies found that more than a quarter bind at least one unintended human protein, and shows these liabilities can sometimes be engineered away.
AbbVie shows that single-atom changes to a molecular glue degrader can reprogram which cellular disposal machinery it recruits — turning ligase choice into a tunable design parameter.
A new antibody blocks a cancer-linked receptor by gripping two separate loops on its surface at once, offering an early proof-of-concept for a target that's historically been hard to drug with antibodies.
A population PK analysis across 2,744 patients shows that a widely-used eye biologic's extended dosing interval comes from a genuine formulation effect on ocular clearance, not just from giving a bigger dose.
Germinal co-optimizes CDR sequence (IgLM) and structure (AlphaFold-Multimer) to design epitope-targeted nanobodies de novo, achieving 4-22% binding success with 43-101 designs tested per target — no starting binder required.
A VHH-VHH bispecific (TCRm Bi-NbTE) simultaneously engages CD3ε and pMHC-I tumor complexes, redirecting T cells to kill tumor cells via intracellular antigens — with in vivo efficacy in CDX and PDX xenografts.
Local fine-tuning of a PLM on 240k yeast-display CDR-H3 variants raises polyreactivity prediction success from 0% (base model) to 66.6% — practical demonstration that foundation models need domain adaptation for narrow drug-optimization tasks.
pH-dependent VHH engineering — 227-fold difference in dissociation rate between neutral and acidic pH — extends GH mimetic activity from 6 days to >15 days in rats, achieving ultra-long-acting PK via FcRn recycling logic in a VHH format.
T-Bren (BL-M07D1, DAR-8, cathepsin B-cleavable, topo I payload) achieves 81.5% ORR in HER2-positive and 69.5% in HER2-low breast cancer across 253 patients; RP2D 4.4 mg/kg Q3W.
ASO cargo inverts the TfR1 affinity-transcytosis relationship in Brainshuttles; a bispecific TfR1×CD98hc format rescues BBB delivery by engaging two distinct trafficking pathways simultaneously.
Ustekinumab + guselkumab variable regions combined into biparatopic 1+1 IgG and 2+2 Fab-IgG formats. Picomolar SPR affinities with avidity enhancement; dual-epitope engagement confirmed by bridging SPR and mass photometry. Functional neutralization equivalent to equimolar antibody mixture — a clean engineering framework without synergistic potency gain.
RNA Pol II miRNA targeting FUT8 in CHO: >90% afucosylation (HILIC-HPLC), no fucosylated product by intact MS, no titer loss. Beats shRNA (U6 promoter) which causes Dicer saturation → residual fucosylation + reduced titers. Clean solution to the afucosylation-vs-yield tradeoff in antibody manufacturing.
117 heavily pre-treated NSCLC patients, 19% ORR (29% taxane-naive nonsquamous), 11.3-month median DOR. IB6 expressed in 92% of biopsies. First JCO readout for an IB6-directed ADC.
Phage + hybridoma screen → TFPI-blocking mAb optimized to ~5.72 nM affinity for PK (not the tightest binder). Now FDA-approved as Hympavzi. Case study in deliberate affinity de-optimization as a PK lever.
ADCs targeting L1CAM — a marker of metastasis-initiating stem cells — achieve complete tumor regression and 100% survival in PDX lung metastasis models at 1 mg/kg with a non-cleavable linker to PNU-159682.
Bispecific ADC simultaneously targeting B7-H3 and PSMA outperforms single-target ADCs in prostate cancer CDX/PDX models by exploiting bystander killing and dual-antigen redundancy against heterogeneous tumors. FDA IND cleared.
MD simulations show nanobody CDR3 loops are intrinsically disordered in solution — not just flexible. Adaptive disorder enables binding to concave epitopes. CDR1/2 are rigid anchors; CDR3 is a conformationally malleable binding arm.
VHH-based bispecific T cell engager co-engaging oncofetal antigen 5T4 and Vδ2-TCR kills solid tumor cells in patient-derived 3D models without cytotoxicity against healthy 5T4-expressing tissue.
Four papers on targeted ADC delivery, disordered-protein degradation, short-lived anti-PD-L1 for Alzheimer's, and spatial QSP for liver-cancer immunotherapy.